ESMO 2025 breast cancer abstracts bring key updates. For example, Dr. Paolo Tarantino from Dana-Farber chose this top 10 list…
Browsing: TNBC
The ESMO 2025 Congress, held October 17-21 in Berlin, will feature exciting breast cancer trials that could improve patient care.…
On September 6, 2025, at the MOASC and ANCO Immuno-Oncology Symposium, Dr. Alexis LeVee, MD, from UCLA’s Division of Hematology/Oncology,…
Nicholas Robert, MD – Chief Medical Officer of Ontada Nicholas J. Robert, the chief medical officer at Ontada, is responsible…
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series…
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel…
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test…
Overview of the ASCENT Trial and Trodelvy The ASCENT Trial (NCT02574455) is a Phase III study that compares Trodelvy (Sacituzumab…